Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1953 1
1954 3
1955 2
1959 2
1960 3
1961 2
1962 3
1963 3
1964 3
1968 2
1969 1
1970 2
1972 1
1973 1
1974 3
1975 6
1977 4
1978 3
1979 2
1981 2
1982 1
1983 4
1984 1
1986 4
1987 5
1988 3
1989 2
1991 5
1992 9
1993 1
1994 1
1995 3
1996 3
1997 2
1998 1
2000 1
2001 1
2002 4
2003 9
2004 7
2005 4
2006 7
2007 7
2008 3
2009 7
2010 9
2011 13
2012 9
2013 16
2014 16
2015 18
2016 10
2017 16
2018 11
2019 5
2020 12
2021 15
2022 12
2023 19
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

311 results

Results by year

Filters applied: . Clear all
Page 1
Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, December 2022-January 2023.
Link-Gelles R, Ciesla AA, Roper LE, Scobie HM, Ali AR, Miller JD, Wiegand RE, Accorsi EK, Verani JR, Shang N, Derado G, Britton A, Smith ZR, Fleming-Dutra KE. Link-Gelles R, et al. Among authors: wiegand re. MMWR Morb Mortal Wkly Rep. 2023 Feb 3;72(5):119-124. doi: 10.15585/mmwr.mm7205e1. MMWR Morb Mortal Wkly Rep. 2023. PMID: 36730051 Free PMC article.
Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection - Increasing Community Access to Testing Program, United States, September-November 2022.
Link-Gelles R, Ciesla AA, Fleming-Dutra KE, Smith ZR, Britton A, Wiegand RE, Miller JD, Accorsi EK, Schrag SJ, Verani JR, Shang N, Derado G, Pilishvili T. Link-Gelles R, et al. Among authors: wiegand re. MMWR Morb Mortal Wkly Rep. 2022 Dec 2;71(48):1526-1530. doi: 10.15585/mmwr.mm7148e1. MMWR Morb Mortal Wkly Rep. 2022. PMID: 36454688 Free PMC article.
Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19-Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions - VISION Network, September 2022-April 2023.
Link-Gelles R, Weber ZA, Reese SE, Payne AB, Gaglani M, Adams K, Kharbanda AB, Natarajan K, DeSilva MB, Dascomb K, Irving SA, Klein NP, Grannis SJ, Ong TC, Embi PJ, Dunne MM, Dickerson M, McEvoy C, Arndorfer J, Naleway AL, Goddard K, Dixon BE, Griggs EP, Hansen J, Valvi N, Najdowski M, Timbol J, Rogerson C, Fireman B, Fadel WF, Patel P, Ray CS, Wiegand R, Ball S, Tenforde MW. Link-Gelles R, et al. Among authors: wiegand r. MMWR Morb Mortal Wkly Rep. 2023 May 26;72(21):579-588. doi: 10.15585/mmwr.mm7221a3. MMWR Morb Mortal Wkly Rep. 2023. PMID: 37227984 Free PMC article.
Influenza vaccine effectiveness against influenza-A-associated emergency department, urgent care, and hospitalization encounters among U.S. adults, 2022-2023.
Tenforde MW, Weber ZA, Yang DH, DeSilva MB, Dascomb K, Irving SA, Naleway AL, Gaglani M, Fireman B, Lewis N, Zerbo O, Goddard K, Timbol J, Hansen JR, Grisel N, Arndorfer J, McEvoy CE, Essien IJ, Rao S, Grannis SJ, Kharbanda AB, Natarajan K, Ong TC, Embi PJ, Ball SW, Dunne MM, Kirshner L, Wiegand RE, Dickerson M, Patel P, Ray C, Flannery B, Garg S, Adams K, Klein NP. Tenforde MW, et al. Among authors: wiegand re. J Infect Dis. 2023 Dec 2:jiad542. doi: 10.1093/infdis/jiad542. Online ahead of print. J Infect Dis. 2023. PMID: 38041853
Conservation of docosahexaenoic acid in the retina.
Anderson RE, O'Brien PJ, Wiegand RD, Koutz CA, Stinson AM. Anderson RE, et al. Among authors: wiegand rd. Adv Exp Med Biol. 1992;318:285-94. doi: 10.1007/978-1-4615-3426-6_25. Adv Exp Med Biol. 1992. PMID: 1386176 Review.
Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19-Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions - VISION Network, September 2022-April 2023.
Link-Gelles R, Weber ZA, Reese SE, Payne AB, Gaglani M, Adams K, Kharbanda AB, Natarajan K, DeSilva MB, Dascomb K, Irving SA, Klein NP, Grannis SJ, Ong TC, Embi PJ, Dunne MM, Dickerson M, McEvoy C, Arndorfer J, Naleway AL, Goddard K, Dixon BE, Griggs EP, Hansen J, Valvi N, Najdowski M, Timbol J, Rogerson C, Fireman B, Fadel WF, Patel P, Ray CS, Wiegand R, Ball S, Tenforde MW. Link-Gelles R, et al. Among authors: wiegand r. Am J Transplant. 2023 Jul;23(7):1062-1076. doi: 10.1016/j.ajt.2023.06.004. Am J Transplant. 2023. PMID: 37394267 No abstract available.
311 results